Recent Updates
Recently added Catalysts

Kristalose

Phase 1

Bowel Evacuant Prior to Colonoscopy | Small molecule | Gastrointestinal |Cumberland Pharmaceuticals Inc.|Last Updated: Oct 6, 2011

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment20
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01256541Kristalose as Bowel Evacuant Prior to ColonoscopyPHASE1 COMPLETED 20Dec 1, 2010Sep 1, 2011Oct 6, 20111 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Hydrogen and Methane Gas Production
3 months

To evaluate the primary objective of hydrogen and methane gas production as measured by: • Pre- and post-dose breath analysis for hydrogen and methane gas.

Secondary Endpoints
Efficacy
3 months
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
KristaloseEXPERIMENTALKristalose as Bowel Evacuant
Interventions
NameTypeDescription
KristaloseDRUGThe dosing regimen of Kristalose will be nine 20-gram doses (one dose every 30 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: Patients requiring bowel evacuation for colonoscopy Exclusion Criteria: 1. Patients with galactosemia (galactose-sensitive diet). 2. Patients known to be hypersensitive to any of the components of Kristalose. 3. Patients with possible bowel obstruction, previous colonic surger...

Countries:United States
Unlock Eligibility Criteria